SUNNYVALE, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (“Intuitive” or the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2019.
Q1 Highlights
- Worldwide da Vinci procedures grew approximately 18% compared with the first quarter of 2018, driven primarily by growth in U.S. general surgery procedures and worldwide urologic procedures.
- The Company shipped 235 da Vinci Surgical Systems, an increase of 27% compared with 185 in the first quarter of 2018.
- The Company grew its installed base to 5,114 systems as of March 31, 2019, an increase of 13% compared with 4,528 as of the end of the first quarter of 2018.
- First quarter 2019 revenue of $974 million grew approximately 15% compared with $848 million for the first quarter of 2018.
- First quarter 2019 GAAP net income was $307 million, or $2.56 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
- First quarter 2019 non-GAAP* net income was $312 million, or $2.61 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
- In February 2019, the Company received U.S. Food and Drug Administration (“FDA”) clearance for the IonTM endoluminal system, the Company’s new flexible robotic-assisted catheter-based platform, designed to navigate through very small lung airways to reach peripheral nodules for biopsies.
- In February 2019, the Company received FDA clearance for the IRISTM augmented reality product, designed to aid surgeons in both pre- and intra-operative settings by delivering a 3D image of the patient anatomy.
- In March 2019, the Company received FDA clearance for the da Vinci SP® Surgical System for use in certain transoral otolaryngology procedures in adults.
Q1 Financial Summary
Gross profit, income from operations, net income, net income per diluted share, and diluted shares are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.
First quarter 2019 revenue was $974 million, an increase of approximately 15% compared with $848 million in the first quarter of 2018. Higher first quarter revenue was driven by increased procedures and systems placements.
First quarter 2019 instrument and accessory revenue increased by approximately 20% to $552 million, compared with $460 million for the first quarter of 2018, primarily driven by approximately 18% growth in da Vinci procedure volume.
First quarter 2019 systems revenue increased by approximately 6% to $248 million, compared with $235 million for the first quarter of 2018. The Company shipped 235 da Vinci Surgical Systems in the first quarter of 2019, compared with 185 in the first quarter of 2018. The first quarter 2019 system shipments included 78 systems shipped under operating lease and usage-based arrangements, compared with 43 during the first quarter of 2018.
First quarter 2019 GAAP income from operations decreased to $252 million, compared with $277 million in the first quarter of 2018. First quarter 2019 GAAP income from operations included intangible asset charges of $30 million, compared with $8 million in the first quarter of 2018, and share-based compensation expense of $76 million, compared with $58 million in the first quarter of 2018. First quarter 2019 non-GAAP* income from operations increased to $362 million, compared with $346 million in the first quarter of 2018.
First quarter 2019 GAAP net income was $307 million, or $2.56 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018. First quarter 2019 GAAP net income included excess tax benefits of $73 million, or $0.61 per share, compared with $55 million, or $0.46 per share, for the first quarter of 2018.
First quarter 2019 non-GAAP* net income was $312 million, or $2.61 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
The Company ended the first quarter of 2019 with $5.1 billion in cash, cash equivalents, and investments, an increase of $230 million during the quarter, primarily driven by cash generated from operations.
Commenting on the announcement, Intuitive CEO Gary Guthart said, “We are pleased with our first quarter procedure and da Vinci system placements. Our teams continue to work closely with hospitals, physicians and their care teams in pursuit of better outcomes, decreased variability, better experiences for both physicians and patients and, ultimately, lowering the total cost of care.”
Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at: https://isrg.gcs-web.com/.
Webcast and Conference Call Information
Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the first quarter 2019 financial results. The call is being webcast by Nasdaq OMX and can be accessed at Intuitive’s website at www.intuitive.com or by dialing (800) 230-1059 or (612) 234-9959.
About Intuitive
Intuitive (Nasdaq:ISRG), headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. At Intuitive, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.
Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings, and develops, manufactures and markets the da Vinci® surgical system and the Ion™ endoluminal system.
Da Vinci®, da Vinci SP®, IonTM, and IRISTM are trademarks or registered trademarks of Intuitive Surgical, Inc.
For more information, please visit the Company’s website at www.intuitive.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the Company continuing to work closely with hospitals, physicians, and care teams in pursuit of better outcomes, decreased variability, better experiences, and lowering the total cost of care. These forward-looking statements are necessarily estimates reflecting the best judgment of the Company’s management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the timing and success of product development and market acceptance of developed products, including, but not limited to, the Ion endoluminal system, the da Vinci SP surgical system, and 3rd generation stapling platform; the impact of global and regional economic and credit market conditions on healthcare spending; competition in the medical device industry and in the specific markets of surgery in which the Company operates; risks associated with our operations outside of the United States; product liability and other litigation claims; adverse publicity regarding the Company and the safety of the Company’s products and adequacy of training; unanticipated manufacturing disruptions or the inability to meet demand for products; the results of legal proceedings to which the Company is or may become a party; the Company’s reliance on sole and single source suppliers; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; healthcare reform legislation in the United States and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; procedure counts; regulatory approvals, clearances and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; intellectual property positions and litigation; the Company’s ability to expand into foreign markets; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risk factors under the heading “Risk Factors” in the Company’s report on Form 10-K for the year ended December 31, 2018, as updated by the Company’s other filings with the Securities and Exchange Commission. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
*About Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income, non-GAAP net income per diluted share (“EPS”), and non-GAAP diluted shares. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding items such as intangible asset charges, share-based compensation (“SBC”) expenses, and other special items. Intangible asset charges consist of non-cash charges, such as the amortization of intangible assets, as well as in-process R&D charges. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to its historical performance and liquidity. The Company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company’s business.
Non-GAAP gross profit. The Company defines non-GAAP gross profit as gross profit excluding intangible asset charges, expenses related to SBC, and litigation charges and recoveries.
Non-GAAP income from operations. The Company defines non-GAAP income from operations as income from operations excluding intangible asset charges, certain acquisition related items for the re-measurement of contingent considerations, expenses related to SBC, and litigation charges and recoveries.
Non-GAAP net income and EPS. The Company defines non-GAAP net income as net income (loss) excluding intangible asset charges; expenses related to SBC; litigation charges and recoveries; non-cash impairment charges; certain acquisition related items for the re-measurement of contingent considerations; adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects; and tax adjustments including the excess tax benefits or deficiencies associated with SBC arrangements, the one-time impact of the enactment of the 2017 Tax Act, and the net tax effects related to intra-entity transfers of non-inventory assets. The Company excludes the one-time impact of the enactment of the 2017 Tax Act because it is discrete in nature as well as the excess tax benefits or deficiencies associated with SBC arrangements and the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers as the Company does not believe these items correlate with the on-going results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company’s operating results. The Company’s calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income divided by non-GAAP diluted shares which are calculated as GAAP weighted average outstanding shares plus dilutive potential shares outstanding during the period.
There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income, and non-GAAP EPS exclude items such as intangible asset charges, re-measurement of contingent considerations, SBC, excess tax benefits or deficiencies associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfer of non-inventory assets, which are primarily recurring items. SBC has been and will continue to be for the foreseeable future a significant recurring expense in the Company’s business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income and non-GAAP EPS and evaluating non-GAAP net income and non-GAAP EPS together with net income (loss) and net income (loss) per share calculated in accordance with GAAP.
INTUITIVE SURGICAL, INC.
UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN MILLIONS, EXCEPT PER SHARE DATA)
| Three months ended | |||||||||||
| March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
| Revenue: | |||||||||||
| Instruments and accessories | $ | 552.3 | $ | 539.3 | $ | 460.3 | |||||
| Systems | 247.5 | 340.6 | 234.5 | ||||||||
| Services | 173.9 | 166.6 | 152.7 | ||||||||
| Total revenue | 973.7 | 1,046.5 | 847.5 | ||||||||
| Cost of revenue: | |||||||||||
| Product | 246.4 | 251.5 | 201.5 | ||||||||
| Service | 57.7 | 59.3 | 52.2 | ||||||||
| Total cost of revenue | 304.1 | 310.8 | 253.7 | ||||||||
| Gross profit | 669.6 | 735.7 | 593.8 | ||||||||
| Operating expenses: | |||||||||||
| Selling, general and administrative (1) | 273.4 | 283.8 | 221.6 | ||||||||
| Research and development | 144.0 | 119.9 | 95.5 | ||||||||
| Total operating expenses | 417.4 | 403.7 | 317.1 | ||||||||
| Income from operations (2) | 252.2 | 332.0 | 276.7 | ||||||||
| Interest and other income, net | 27.5 | 26.8 | 13.2 | ||||||||
| Income before taxes | 279.7 | 358.8 | 289.9 | ||||||||
| Income tax expense (3) | (24.3 | ) | 67.5 | 2.6 | |||||||
| Net income | 304.0 | 291.3 | 287.3 | ||||||||
| Less: net loss attributable to noncontrolling interest in joint venture | (2.5 | ) | (1.2 | ) | (0.3 | ) | |||||
| Net income attributable to Intuitive Surgical, Inc. | $ | 306.5 | $ | 292.5 | $ | 287.6 | |||||
| Net income per share attributable to Intuitive Surgical, Inc.: | |||||||||||
| Basic | $ | 2.67 | $ | 2.56 | $ | 2.55 | |||||
| Diluted (4) | $ | 2.56 | $ | 2.45 | $ | 2.44 | |||||
| Weighted average shares outstanding: | |||||||||||
| Basic | 115.0 | 114.3 | 112.8 | ||||||||
| Diluted | 119.6 | 119.2 | 118.0 | ||||||||
| (1) Selling, general and administrative includes the effect of the following item: | |||||||||||
| Contributions to the Intuitive Foundation | $ | — | $ | 25.2 | $ | — | |||||
| (2) Income from operations includes the effect of the following item: | |||||||||||
| Intangible asset charges | $ | 30.2 | $ | 9.4 | $ | 7.6 | |||||
| (3) Income tax expense includes the effect of the following item: | |||||||||||
| Excess tax benefits related to share-based compensation arrangements | $ | (72.7 | ) | $ | (15.8 | ) | $ | (54.7 | ) | ||
| (4) Diluted net income per share includes the effect of the following items: | |||||||||||
| Contributions to the Intuitive Foundation, net of tax | $ | — | $ | (0.16 | ) | $ | — | ||||
| Intangible asset charges, net of tax | $ | (0.21 | ) | $ | (0.07 | ) | $ | (0.05 | ) | ||
| Excess tax benefits related to share-based compensation arrangements | $ | 0.61 | $ | 0.13 | $ | 0.46 | |||||
INTUITIVE SURGICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(IN MILLIONS)
| March 31, 2019 | December 31, 2018 | ||||||
| Cash, cash equivalents, and investments | $ | 5,064.6 | $ | 4,834.4 | |||
| Accounts receivable, net | 547.6 | 682.3 | |||||
| Inventory | 468.3 | 409.0 | |||||
| Property, plant, and equipment, net | 935.4 | 812.0 | |||||
| Goodwill | 247.5 | 240.6 | |||||
| Deferred tax assets | 392.4 | 428.6 | |||||
| Other assets | 579.1 | 439.8 | |||||
| Total assets | $ | 8,234.9 | $ | 7,846.7 | |||
| Accounts payable and other accrued liabilities | $ | 865.3 | $ | 831.9 | |||
| Deferred revenue | 329.2 | 327.3 | |||||
| Total liabilities | 1,194.5 | 1,159.2 | |||||
| Stockholders’ equity | 7,040.4 | 6,687.5 | |||||
| Total liabilities and stockholders’ equity | $ | 8,234.9 | $ | 7,846.7 | |||
INTUITIVE SURGICAL, INC.
UNAUDITED RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
(IN MILLIONS, EXCEPT PER SHARE DATA)
| Three months ended | ||||||||||||
| March 31, 2019 | December 31, 2018 | March 31, 2018 | ||||||||||
| GAAP gross profit | $ | 669.6 | $ | 735.7 | $ | 593.8 | ||||||
| Share-based compensation expense | 15.1 | 13.5 | 11.9 | |||||||||
| Intangible asset charges | 8.2 | 2.0 | 1.0 | |||||||||
| Non-GAAP gross profit | $ | 692.9 | $ | 751.2 | $ | 606.7 | ||||||
| GAAP income from operations | $ | 252.2 | $ | 332.0 | $ | 276.7 | ||||||
| Share-based compensation expense | 76.1 | 70.4 | 57.5 | |||||||||
| Intangible asset charges | 30.2 | 9.4 | 7.6 | |||||||||
| Litigation charges | — | — | 4.5 | |||||||||
| Acquisition related items | 3.0 | — | — | |||||||||
| Non-GAAP income from operations | $ | 361.5 | $ | 411.8 | $ | 346.3 | ||||||
| GAAP net income attributable to Intuitive Surgical, Inc. | $ | 306.5 | $ | 292.5 | $ | 287.6 | ||||||
| Share-based compensation expense | 76.1 | 70.4 | 57.5 | |||||||||
| Intangible asset charges | 30.2 | 9.4 | 7.6 | |||||||||
| Litigation charges | — | — | 4.5 | |||||||||
| Impairment charges | 1.5 | 1.2 | — | |||||||||
| Acquisition related items | 3.0 | — | — | |||||||||
| Tax adjustments (1) | (101.5 | ) | (20.3 | ) | (69.7 | ) | ||||||
| Adjustments attributable to noncontrolling interest in joint venture | (3.8 | ) | — | — | ||||||||
| Non-GAAP net income attributable to Intuitive Surgical, Inc. | $ | 312.0 | $ | 353.2 | $ | 287.5 | ||||||
| GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted | $ | 2.56 | $ | 2.45 | $ | 2.44 | ||||||
| Share-based compensation expense | 0.64 | 0.59 | 0.49 | |||||||||
| Intangible asset charges | 0.25 | 0.08 | 0.06 | |||||||||
| Litigation charges | — | — | 0.04 | |||||||||
| Impairment charges | 0.01 | 0.01 | — | |||||||||
| Acquisition related items | 0.03 | — | — | |||||||||
| Tax adjustments (1) | (0.85 | ) | (0.17 | ) | (0.59 | ) | ||||||
| Adjustments attributable to noncontrolling interest in joint venture | (0.03 | ) | — | — | ||||||||
| Non-GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted | $ | 2.61 | $ | 2.96 | $ | 2.44 | ||||||
| (1) For the three months ended March 31, 2019, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(72.7) million, or $(0.61) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.09 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.33) per diluted share. | ||||||||||||
Contact: Investor Relations
(408) 523-2161